Four Vanderbilt technologies earned patent protection from the USPTO in December, bringing the total number of patents assigned to Vanderbilt to 23 for the first half of FY14.
Three Vanderbilt technologies received US patent protection in the month of November. One invention includes a compound that targets positive allosteric modulation of the mGlu5 receptor for the treatment of neurological and psychiatric disorders. It was developed at Vanderbilt Center for Neuroscience Drug Discovery which is led by Vanderbilt neuroscientist P.
One quarter into the new fiscal year, more than a dozen Vanderbilt technologies have been awarded patent protection by the USPTO. The four newest, which were issued throughout the month of September, include:
Four new patents protecting Vanderbilt intellectual property were assigned during the month of August. The technologies represent fields such as neuroscience, cellular biology, molecular biology, cancer therapy, and diagnostics.
